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Introduction 25 
Pre-diabetes is a term used to describe the state where blood glucose levels are above normal but 26 
below the threshold for diagnosis of diabetes. An estimated 1 in 3 of the adult population of the UK 27 
fall into this group.
1
 The addition of a coded entry for pre-diabetes to aid adherence to NICE 28 
guidance on follow up of at risk groups is embedding this label within increasing numbers of 29 
patients lifelong medical records. This article discusses the meaning and significance of this new 30 
diagnosis at individual and societal level, the controversy that surrounds it and implications for 31 
policy, practice and research.  32 
 33 
Identification of pre-diabetes 34 
In the UK pre-diabetes is usually diagnosed on the basis of an HbA1c level of 42-47mmol/mol.
2
 The 35 
term is also used to encompass people identified as being at high risk of diabetes by other testing 36 
strategies such as fasting glucose or the OGTT. The groups identified as abnormal by different testing 37 
strategies do not entirely overlap and there is on-going debate about which diagnostic test is most 38 
appropriate and what the cut offs should be.
3
 Despite the limitations of HbA1c in certain groups and 39 
its poor sensitivity and specificity if the OGTT is taken as the gold standard,
4
 its ease of use makes it 40 
the most commonly used diagnostic test.  41 
It is estimated that 5-10% of pre-diabetic people will become diabetic each year with a similar 42 
proportion reverting back to normoglycaemia.
5
 Those with a family history, certain ethnic groups 43 
and women with polycystic ovarian disease or previous gestational diabetes are at higher risk of 44 
progression to diabetes. 45 
NICE guidance on preventing type 2 diabetes encourages individual risk assessment for diabetes and 46 
advises offering fasting glucose or HbA1c testing to those deemed to be at high risk.
2
 For those that 47 
have a high risk score and an abnormal result the guideline advises offering a quality assured 48 
intensive lifestyle change programme and re-measuring weight, BMI and a blood test at least once 49 
per year. This has significant workload implications for general practice and exposes large numbers 50 
of the population to investigations and possible intervention. 51 
 52 
Diabetes prevention programmes 53 
The rationale for identifying those at higher than average risk for developing diabetes is to be able to 54 
intervene to prevent this progression. Internationally, large-scale lifestyle modification programmes 55 
have been developed to try to reduce the rate of development of diabetes, most notably in Finland
6
 56 
and USA.
7
 The Healthier You Diabetes Prevention Programme (DPP) was introduced in England in 57 
2016 and is due to be rolled-out nationwide by 2020. Those referred to the DPP are offered tailored, 58 
personalised lifestyle behaviour change support over at least thirteen face to face sessions, lasting 1-59 
2 hours and providing a minimum of 16 hours of contact time, over at least 9 months, aiming to 60 
reduce their risk of type 2 diabetes.
8
 61 
The ability to offer individuals referral to such a lifestyle intervention programme, potentially 62 
avoiding the need for medication and the development of complications of diabetes is appealing. 63 
However, evidence for the real world efficacy of such programmes is sparse.  64 
A recent meta-analysis of interventions to prevent diabetes in screen detected pre-diabetes 65 
concluded that individually targeted lifestyle interventions have some efficacy in preventing or 66 
delaying the onset of diabetes but the study quality was often low and the effect attenuated with 67 
time from the intervention.
4
 The authors also commented that due to the large number of people 68 
who do not meet the eligibility criteria or decline or fail to complete the intervention, it is not 69 
possible to extrapolate percentage risk reductions seen in trials to a reduction in incidence of 70 
diabetes across an entire community.  71 
A recent large scale randomised controlled trial to evaluate the effect of a type 2 diabetes 72 
prevention lifestyle intervention (Let's Prevent) in a UK community setting failed to show a 73 
statistically significant reduction in progression to type 2 diabetes at 3 years compared to normal 74 
care
9
 i.e. it failed to do the thing that it was supposed to do. Retrospective re-analysis of the data did 75 
show a significant reduction in progression to diabetes in the sub-group of patients who engaged 76 
and then attended subsequent sessions, with the greatest benefit seen for the 29.1% of patients 77 
randomised to the intervention who attended all sessions. Patients were less likely to engage or 78 
attend follow up if they were male, socio-economically deprived, smokers or physically inactive.
10
 79 
These patient groups are at higher risk of developing diabetes than the background population, 80 
therefore failure to reach them with a lifestyle intervention programme has the potential 81 
unintended consequence of increasing health inequity. 82 
To reduce diabetes incidence in the whole population, adequately resourced and integrated public 83 
health, primary care and policy strategies to reduce obesity, reduce sugar intake and increase 84 
physical activity are needed.  Targeting individuals to change their lifestyle is by comparison 85 
expensive and likely to be minimally effective for the health of the population as a whole.  The 86 
groups of people most likely to be able to engage with such lifestyle change programmes are those 87 
with the least barriers to change (income, education levels, an expectation of healthy years lived), 88 
not those that are most at risk of progression to type 2 diabetes and poorer outcomes.  These 89 
psychosocial, cultural and demographic barriers need to be considered and addressed if the 90 
programmes are to be effective.  91 
 92 
Overdiagnosis? 93 
Expanding the definition of what is an abnormal blood sugar result and attaching a new label to this 94 
has consequences both for the individual and for society.
 
 95 
Labelling a person as having a pre-disease may have unintended consequences such as health 96 
anxiety and stigma even though it may never cause them to become unwell. With some comparable 97 
conditions, such as CKD 3, where the distinction between risk factor, biochemical abnormality or 98 
disease can be blurred, explicit discussions are not always had with patients about these labels 99 
(rightly or wrongly).
11
 However, the existence of a diagnosis and referral pathway for those with pre-100 
diabetes attributes significance to the condition as something which requires intervention and 101 
follow up. In an ever increasingly stretched primary care service, the opportunity costs of identifying 102 
and managing a new condition also need to be considered.  103 
The term pre-diabetes is already familiar to healthcare practitioners (medical specialists, nurses, 104 
GPs, allied health professionals) and administrators and is likely to gradually be normalised in lay 105 
conversations.  More widespread acceptance that this pre-diabetic state can be treated may 106 
contribute to an emergent expectation of prescribed medication, with all of the harms that this may 107 
entail. Pharmaceutical companies may see the potential of a huge and growing market for oral 108 
hypoglycaemics and anti-obesity medications linked to more widespread medicalization and public 109 
fears. 110 
 111 
Conclusions 112 
Guidelines and policy dictate that the term pre-diabetes is here to stay and the nationwide rollout of 113 
the Diabetes Prevention Programme means that GPs, practice nurses and healthcare assistants 114 
across England will be having frequent conversations with patients about this acquired health status. 115 
It is therefore incumbent upon us to maximise the benefits and minimise the harms of these 116 
conversations, perhaps creating an opportunity to take ownership of the label as a motivator for 117 
change before it is fixed in the nations psyche as a disease.  118 
 119 
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